Table 1. Bacterial strains used in this study.

Isolate	Relevant characteristic(s)	EPS production (g/l)	Ciprofloxacin MIC (µg/ml)	Exposure [ciprofloxacin](µg/ml)	Source or reference
B. multivorans D2095	Cystic fibrosis clinical isolate, Canada; EPS+ (cepacian)§	3.7±0.1	4	10	[13]
B. multivorans D2214	Cystic fibrosis clinical isolate, Canada; EPS−	0.0	ND	-	[13]
B. multivorans ATCC 17616	Soil isolate, USA; EPS+(cepacian) §	0.3±0.1	1	2.5	[33]
B. cepacia IST408	Cystic fibrosis clinical isolate, Portugal; EPS+ (cepacian) §	1.2±0.5	1	2.5	[34]
B. cepacia ATCC 17759	Soil isolate, Trinidad; EPS+#	ND	1	2.5	[35]
B. cenocepacia J415	Cystic fibrosis clinical isolate, UK; EPS+#	ND	2	5	[36]
B. stabilis LMG14086	Respirator, UK; EPS+#	ND	1	2.5	[37]
B. stabilis LMG18888	Human blood, Belgium; EPS+#	0.2±0.1	1	2.5	[38]
B. vietnamiensis PC259	Cystic fibrosis clinical isolate, USA; EPS+#	ND	1	2.5	[39]
B. ambifaria AMMD	Root-colonizing bacterium, USA; EPS+ (cepacian) §	ND	1	2.5	[40]
B. ambifaria CEP0958	Cystic fibrosis clinical isolate, Australia; EPS+#	3.9± 0.3	1	2.5	[40]
B. dolosa CEP0743	Cystic fibrosis clinical isolate, Canada; EPS+#	1.2±0.4	2	5	D. P. Speert
B. anthina J2552	Soil isolate, UK; EPS+#	ND	1	2.5	[41]
B. anthina FC0974	Cystic fibrosis clinical isolate, Canada; EPS+#	0.4±0.2	1	2.5	D. P. Speert
B. phymatum STM815	Soil isolate, French Guiana; nitrogen fixation; EPS+ (cepacian) §	1.9±0.2	6*	15	[42]
B. xenovorans LB400	Soil isolate, USA; degradation of polychlorinated biphenyl compounds; EPS+ (cepacian) §	5.2±0.2	6*	15	[43]

ND, not determined; ^*MIC determined at 30°C; ^§ the EPS produced by this strain in MM medium is cepacian as determined by condensed-phase infrared spectroscopy [44]; ^# the nature of this EPS was not determined; EPS⁺, producer of exopolysaccharide; EPS⁻, non EPS producer.